GSK Will Seek to Commercialize Viread in China for Hepatitis B

GlaxoSmithKline and Gilead Sciences agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® (tenofovir disoproxil fumarate). GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore, South Korea and Taiwan. Each company will pay royalties to the other on sales in their own territory. Stock Symbols: (NSDQ: GILD) (NYSE: GSK)